gmb-475 (CH Instruments)
90
Structured Review
CH Instruments
gmb-475
Gmb 475, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gmb-475/gmb+475/pmc06893872-161-42-92
Average 90 stars, based on 1 article reviews
Gmb 475, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gmb-475/gmb+475/pmc06893872-161-42-92
Average 90 stars, based on 1 article reviews
gmb-475 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Western Blot:Article Title: Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation Article Snippet: Finally, we confirmed by immunoblot that GMB-475, but not GMB-651, was indeed able to induce degradation of both BCR-ABL1 and ABL1 in primary patient LSCs ( ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 5. caption a7 caption a8 GMB-475 reduces cell viability, induces apoptosis, and degrades BCR-ABL1 in primary CML patient stem/progenitor cells. (A) Cell viability dose response curves for CD34 + cells (patient 1) treated with PROTAC or diastereomer. (B) Annexin V staining healthy donor or CML primary CD34 + cells (patient 4, Chi-square test, ****p<0.0001). (C) Annexin V staining in sorted progenitor (CD34 + /CD38 + ) and stem (CD34 + /CD38 − ) CML cells (patient 1) by Guava Nexin assay (One-way ANOVA, **p<0.01; error bars represent SEM for at least 3 biological replicates). (D) BCR-ABL1 degradation in CML CD34 + /CD38 − cells (patient 1) treated overnight with GMB-475 or diastereomer. Staining:Article Title: Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation Article Snippet: Finally, we confirmed by immunoblot that GMB-475, but not GMB-651, was indeed able to induce degradation of both BCR-ABL1 and ABL1 in primary patient LSCs ( ). fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 5. caption a7 caption a8 GMB-475 reduces cell viability, induces apoptosis, and degrades BCR-ABL1 in primary CML patient stem/progenitor cells. (A) Cell viability dose response curves for CD34 + cells (patient 1) treated with PROTAC or diastereomer. (B) Annexin V staining healthy donor or CML primary CD34 + cells (patient 4, Chi-square test, ****p<0.0001). (C) Annexin V staining in sorted progenitor (CD34 + /CD38 + ) and stem (CD34 + /CD38 − ) CML cells (patient 1) by Guava Nexin assay (One-way ANOVA, **p<0.01; error bars represent SEM for at least 3 biological replicates). (D) BCR-ABL1 degradation in CML CD34 + /CD38 − cells (patient 1) treated overnight with GMB-475 or diastereomer. |